Drug Trial Radar · NCT04053634
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
689
Actual
Start
Aug 26, 2019
Primary completion
Jul 28, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count. The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
BenralizumabBiological
Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
PlaceboBiological
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.Time frame: up to Week 56
- Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56
Locations
342 sites in 30 countries. Site status is shown where the registry gives one.
Research Site
Surprise, Arizona
Research Site
Little Rock, Arkansas
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Northridge, California
Research Site
Palm Springs, California
Research Site
Westminster, California
Research Site
Stamford, Connecticut
Research Site
Clearwater, Florida
Research Site
Daytona Beach, Florida
Research Site
Edgewater, Florida
Research Site
Jacksonville, Florida
Research Site
Jacksonville, Florida
Research Site
Kissimmee, Florida
Research Site
Kissimmee, Florida
Research Site
Leesburg, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Pensacola, Florida
Research Site
St. Petersburg, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Lawrenceville, Georgia
Research Site
Rincon, Georgia
Research Site
Chicago, Illinois
Research Site
O'Fallon, Illinois
Research Site
Peoria, Illinois
Research Site
Michigan City, Indiana
Research Site
Iowa City, Iowa
Research Site
Kansas City, Kansas
Research Site
Georgetown, Kentucky
Research Site
Baltimore, Maryland
Research Site
Columbia, Maryland
Research Site
Boston, Massachusetts
Research Site
North Dartmouth, Massachusetts
Research Site
Farmington Hills, Michigan
Research Site
Lincoln, Nebraska
Research Site
Omaha, Nebraska
Research Site
Toms River, New Jersey
Showing 40 of 342 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.